GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: BMS1001 | Example 1001 [WO2015160641A2]
                                 
                                                         
                            
                            
                            
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments | 
| Small molecule checkpoint inhibitors are being developed as complementary and potentially synergistic therapeutics to the currently approved monoclonal antibodies used to inhibit the PD-1/PD-L1 checkpoint in immuo-oncology applications. Inhibitors of the PD-1/PD-L1 immune checkpoint functionally alleviate the PD-L1-induced exhaustion of T cells and re-instate effector cell-mediated tumour elimination, be they small molecules like BMS-1001 and BMS-1166 [2], or monoclonal antibodies like atezolizumab, durvalumab, pembrolizumab or nivolumab. |